Omeros | OMER - Sales Revenues


Omeros reported $0 in Sales Revenues for its fiscal quarter ending in March of 2022.





Sales Change Date
Adma Biologics USD 114.5M 24.66M Mar/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Cytokinetics USD 28.6M 9.25M Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 425.49M 119.53M Jun/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Pacira USD 192.4M 15.4M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Rockwell Medical USD 25.83M 3.15M Jun/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026